vimarsana.com
Home
Live Updates
Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting : vimarsana.com
Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting
/PRNewswire/ -- Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the...
Related Keywords
Chicago ,
Illinois ,
United States ,
Texas ,
California ,
South San Francisco ,
American ,
Deyaa Adib ,
Prnewswire Triumvira Immunologics ,
David Schull ,
Benjaminl Schlechter ,
Benjamin Schlechter ,
Ignacio Guerrero Ros ,
Triumvira Immunologics ,
Dana Farber Cancer Institute ,
Harvard Medical School ,
American Society ,
Triumvira Immunologics Inc ,
Society Of Clinical Oncology ,
Annual Meeting ,
Senior Physician ,
Gastrointestinal Oncology ,
Chief Medical Officer ,
Principal Investigator ,
Investigating Safety ,
Refractory Solid Tumors ,
Attending Physician ,
Medical Oncology ,
Dana Farber Cancer ,
Developmental Therapeutics ,
Session Display Date ,
Discussion Session Date ,
Antigen Coupler ,
Health Care Amp Hospitals ,
Biotechnology ,
Medical Pharmaceuticals ,
Clinical Trials Amp Medical Discoveries ,
Trade Show News ,
New Products Amp Services ,
vimarsana.com © 2020. All Rights Reserved.